This case indicates three co-mutations, including SETBP1, DDX41 and TP53, may led to rapid disease progression, and underscores the challenges in managing MDS progressing to sAML, highlighting the prognostic value of genetic mutations detected through multiple genetic tests and the need for further treatment strategies. The gene discussed is TP53; the disease is myelodysplastic syndrome.